Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | FCER2 | P06734 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356941 | 0.81 | SLC1A1 (0.54) | CTSSCTSKSLC1A1FCER2MMP3 | |
| SCHEMBL23356943 | 0.81 | SLC1A1 (0.54) | CTSSCTSKSLC1A1FCER2MMP3 | |
| SCHEMBL4677385 | 0.80 | FCER2 (0.45) | CTSSCTSKSLC1A1FCER2MMP3 | |
| SCHEMBL21447200 | 0.79 | CTSS (0.69) | CTSSCTSKSCN9A | |
| SCHEMBL30471239 | 0.78 | SLC1A1 (0.47) | CTSSCTSKSLC1A1MAOBMAOA | |
| SCHEMBL4677869 | 0.78 | HPGDS (0.48) | SLC1A1FCER2MMP3MMP9ROCK1 | |
| SCHEMBL4683513 | 0.76 | SLC1A1 (0.41) | SLC1A1FCER2MMP3MMP9 | |
| SCHEMBL4677881 | 0.76 | FCER2 (0.52) | FCER2MMP3MMP9 | |
| SCHEMBL22204669 | 0.75 | MEN1 (0.50) | CTSSCTSKMAOBMAOASCN9A | |
| SCHEMBL9989813 | 0.75 | SLC1A1 (0.55) | SLC1A1MAOBMAOASCN9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | CTSS 7/4885CTSK 5/4885SLC1A1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.